Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. Breast cancer anti-estrogen resistance gene 3 was identified in the search for genes involved in the development of estrogen resistance. The gene encodes a component of intracellular signal transduction that causes estrogen-independent proliferation in human breast cancer cells. The protein contains a putative src homology 2 (SH2) domain, a hallmark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48.[6]
Dorssers LC, van Agthoven T (1997). "Genetic mechanisms of estrogen-independence in breast cancer". Pathol. Res. Pract. 192 (7): 743–51. doi:10.1016/S0344-0338(96)80096-3. PMID8880875.
Johnston SR (1998). "Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications". Anticancer Drugs. 8 (10): 911–30. doi:10.1097/00001813-199711000-00002. PMID9436634.
Beausoleil SA, Villén J, Gerber SA, et al. (2006). "A probability-based approach for high-throughput protein phosphorylation analysis and site localization". Nat. Biotechnol. 24 (10): 1285–92. doi:10.1038/nbt1240. PMID16964243. S2CID14294292.